JP2023513794A5 - - Google Patents

Info

Publication number
JP2023513794A5
JP2023513794A5 JP2022549145A JP2022549145A JP2023513794A5 JP 2023513794 A5 JP2023513794 A5 JP 2023513794A5 JP 2022549145 A JP2022549145 A JP 2022549145A JP 2022549145 A JP2022549145 A JP 2022549145A JP 2023513794 A5 JP2023513794 A5 JP 2023513794A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
cycloalkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018040 external-priority patent/WO2021163629A1/en
Publication of JP2023513794A publication Critical patent/JP2023513794A/ja
Publication of JP2023513794A5 publication Critical patent/JP2023513794A5/ja
Pending legal-status Critical Current

Links

JP2022549145A 2020-02-14 2021-02-12 Ulk1/2の阻害剤およびその使用方法 Pending JP2023513794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977040P 2020-02-14 2020-02-14
US62/977,040 2020-02-14
PCT/US2021/018040 WO2021163629A1 (en) 2020-02-14 2021-02-12 Inhibitors of ulk1/2 and methods of using same

Publications (2)

Publication Number Publication Date
JP2023513794A JP2023513794A (ja) 2023-04-03
JP2023513794A5 true JP2023513794A5 (cg-RX-API-DMAC10.html) 2024-02-20

Family

ID=77292760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549145A Pending JP2023513794A (ja) 2020-02-14 2021-02-12 Ulk1/2の阻害剤およびその使用方法

Country Status (8)

Country Link
US (1) US20230135635A1 (cg-RX-API-DMAC10.html)
EP (1) EP4103182A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023513794A (cg-RX-API-DMAC10.html)
KR (1) KR20220153581A (cg-RX-API-DMAC10.html)
CN (1) CN115515589A (cg-RX-API-DMAC10.html)
AU (1) AU2021218739A1 (cg-RX-API-DMAC10.html)
CA (1) CA3171187A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021163629A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594277B2 (en) 2020-02-14 2026-04-07 Salk Institute For Biological Studies Macrocyclic ULK1/2 inhibitors
US20230332243A1 (en) * 2020-09-30 2023-10-19 Salk Institute For Biological Studies Patient selection biomarkers for treatment with ulk inhibitors
WO2023134582A1 (zh) * 2022-01-14 2023-07-20 上海立森印迹医药技术有限公司 一种嘧啶-2,4-二胺衍生物及其制备方法和用途
WO2024140401A1 (zh) * 2022-12-30 2024-07-04 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物以及包括其的组合物
CN116768885B (zh) * 2023-03-14 2026-03-24 浙江大学 N2-取代双环-2-氨基嘧啶类衍生物、其制备方法及医药用途
WO2024233766A1 (en) * 2023-05-10 2024-11-14 Erasca, Inc. Macrocyclic ulk1/2 inhibitors and their use thereof
CN122180668A (zh) * 2023-09-01 2026-06-09 深圳众格生物科技有限公司 Ulk1抑制剂及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2006129100A1 (en) * 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2007028445A1 (en) * 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
DK2089369T3 (da) * 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
US20100130496A1 (en) * 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
CN101903357A (zh) * 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
WO2009158431A2 (en) * 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
BR112015030518A2 (pt) * 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
CN106536503B (zh) * 2014-04-18 2019-09-06 北京澳合药物研究院有限公司 一种酪氨酸激酶抑制剂及其用途
US10053458B2 (en) * 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
ES2914099T3 (es) * 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
ES2899913T3 (es) * 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
WO2016090079A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
CA3040173A1 (en) * 2016-10-18 2018-04-26 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
US11180482B2 (en) * 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
EP3620457A4 (en) * 2017-05-02 2021-01-06 Korea Research Institute of Chemical Technology PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE

Similar Documents

Publication Publication Date Title
JP6553551B2 (ja) B型肝炎抗ウイルス剤
CN1826313B (zh) 选择性雄激素受体调节剂的大规模合成
JP2015523339A5 (cg-RX-API-DMAC10.html)
JP2009518296A5 (cg-RX-API-DMAC10.html)
JP2024501641A5 (cg-RX-API-DMAC10.html)
JP2009504803A5 (cg-RX-API-DMAC10.html)
JP2022537521A5 (cg-RX-API-DMAC10.html)
JP2006515585A5 (cg-RX-API-DMAC10.html)
JP2025509438A5 (cg-RX-API-DMAC10.html)
AU2018209175B2 (en) Therapeutic inhibitors of the reverse mode of ATP synthase
RU2010100821A (ru) Производные азапептидов
JP2021526017A5 (cg-RX-API-DMAC10.html)
JP2025505644A5 (cg-RX-API-DMAC10.html)
JP2007532627A5 (cg-RX-API-DMAC10.html)
JP2023538524A5 (cg-RX-API-DMAC10.html)
ES2488821T3 (es) Proceso de preparación de un compuesto antiviral
JP6618550B2 (ja) 乳癌の予防又は治療用の化合物
JP2022544803A5 (cg-RX-API-DMAC10.html)
JP2007536262A5 (cg-RX-API-DMAC10.html)
TW200813066A (en) Novel compounds
JPWO2003018010A1 (ja) 動脈硬化作用に基づく疾患の予防及び/または治療薬
JP2006500372A5 (cg-RX-API-DMAC10.html)
JP2007509052A5 (cg-RX-API-DMAC10.html)
JP2008520673A (ja) Hcv阻害剤
JP2023518208A5 (cg-RX-API-DMAC10.html)